FV-100

Last updated
FV-100
Cf1743.png
Names
IUPAC name
3-(2-Deoxy-β-D-erythro-pentofuranosyl)-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
Systematic IUPAC name
3-[(2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(4-pentylphenyl)furo[2,3-d]pyrimidin-2(3H)-one
Other names
Cf1743
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
PubChem CID
UNII
  • InChI=1S/C22H26N2O5/c1-2-3-4-5-14-6-8-15(9-7-14)18-10-16-12-24(22(27)23-21(16)29-18)20-11-17(26)19(13-25)28-20/h6-10,12,17,19-20,25-26H,2-5,11,13H2,1H3/t17-,19+,20+/m0/s1
    Key: MFGSDSRTGUVZQG-DFQSSKMNSA-N
  • CCCCCC1=CC=C(C=C1)C2=CC3=CN(C(=O)N=C3O2)[C@H]4C[C@@H]([C@H](O4)CO)O
Properties
C22H26N2O5
Molar mass 398.459 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

FV-100, also known as Cf1743, is an orally available nucleoside analogue drug [1] with antiviral activity. [2] It may be effective against shingles. [3]

It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium. [4]

Clinical trials

FV-100 was tested against valaciclovir in a phase II trial in patients with herpes zoster. The trial was sponsored by Bristol-Myers Squibb. [5] The drug is currently being developed by ContraVir Pharmaceuticals, Inc., Edison, New Jersey. [6] It has reached Phase III clinical trials. [7]

References

  1. ↑ Inhibitex Completes Phase I Clinical Trials For FV-100 And Selects Lead HCV Compounds For Advanced Preclinical Studies, 2009, archived from the original on 2009-02-15, retrieved 2010-04-08
  2. ↑ McGuigan, Christopher; Balzarini, Jan (2009). "FV100 as a new approach for the possible treatment of varicella-zoster virus infection". Journal of Antimicrobial Chemotherapy . 64 (4): 671–673. doi: 10.1093/jac/dkp294 . PMID   19679595.
  3. ↑ Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J (Jul 2017). "FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial". J Med Virol. 89 (7): 1255–1264. doi:10.1002/jmv.24750. PMC   6139434 . PMID   27943311.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ↑ Cardiff School of Pharmacy; Pharmaceutical Sciences, Step forward for shingles drug - FV100. Shows structure of FV100.
  5. ↑ A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster, 23 September 2015
  6. ↑ "ContraVir Pharmaceuticals: FDA Meeting About Antiviral Drug Trial.", Drug Discovery & Development, January 2015
  7. ↑ De Clercq E, Li G (Jul 2016). "Approved Antiviral Drugs over the Past 50 Years". Clin Microbiol Rev. 29 (3): 695–747. doi:10.1128/CMR.00102-15. PMC   4978613 . PMID   27281742.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.